Literature DB >> 9027268

Health and functional status of long-term survivors of bone marrow transplantation. EBMT Working Party on Late Effects and EULEP Study Group on Late Effects. European Group for Blood and Marrow Transplantation.

T Duell1, M T van Lint, P Ljungman, A Tichelli, G Socié, J F Apperley, M Weiss, A Cohen, E Nekolla, H J Kolb.   

Abstract

BACKGROUND: Although many patients now survive the short-term complications of bone marrow transplantation for life-threatening hematologic disease, information on the health and activity of long-term survivors is sparse.
OBJECTIVE: To evaluate the morbidity and mortality of patients surviving more than 5 years after allogeneic bone marrow transplantation.
DESIGN: Retrospective, multicenter study. PATIENTS: 798 recipients of bone marrow transplants (477 adults, 321 children) from 43 European centers. Patients had received transplants before December 1985 and had survived at least 5 years. Patients had received allogeneic or syngeneic bone marrow for leukemia, lymphoma, inborn diseases of the hematopoietic and immune systems, and severe aplastic anemia. MEASUREMENTS: Survival, clinical performance according to Karnofsky score (in increments of 10%), and social reintegration were assessed as outcomes. Patient age and sex, primary disease and status at transplantation, histocompatibility of the donor, conditioning regimen, type of prophylaxis of graft-versus-host disease, and acute and chronic graft-versus-host disease were evaluated as variables.
RESULTS: For the 55 5-year survivors, actuarial mortality was 8% at 10 years and 14% at 15 years. The leading causes of death were disease recurrence (21 patients), chronic graft-versus-host disease with complicating infections and lung disease (11 patients), secondary cancer (8 patients), and the acquired immunodeficiency syndrome (AIDS) (5 patients). When patients with recurrent disease were excluded, late death was associated with chronic graft-versus-host disease (P < 0.001), occurrence of secondary cancer (P < 0.001), male sex of the patient (P = 0.05), and female sex of the donor (P = 0.002). Clinical performance was normal (Karnofsky score, 100%) or minimally reduced (Karnofsky score, 90%) in 93% of patients; 89% of patients resumed full-time work or school. Reduced performance status and incomplete resumption of social activity were associated with chronic graft-versus-host disease, recurrent leukemia, AIDS, secondary cancer, organ dysfunction, and neurologic or psychological problems. Other risk factors for incomplete resumption of social activity were female sex (P = 0.002) and older age at transplantation (P = 0.001).
CONCLUSIONS: More than 5 years after bone marrow transplantation, most patients were in good health (93%) and had returned to full-time work or school (89%). Recurrence of the primary disease, secondary cancer, and chronic graft-versus-host disease and its sequelae remain problems for some patients.

Entities:  

Mesh:

Year:  1997        PMID: 9027268     DOI: 10.7326/0003-4819-126-3-199702010-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  53 in total

1.  Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.

Authors:  Nandita Khera; Barry Storer; Mary E D Flowers; Paul A Carpenter; Yoshihiro Inamoto; Brenda M Sandmaier; Paul J Martin; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2011-12-05       Impact factor: 44.544

2.  Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.

Authors:  Smita Bhatia; Liton Francisco; Andrea Carter; Can-Lan Sun; K Scott Baker; James G Gurney; Philip B McGlave; Auayporn Nademanee; Margaret O'Donnell; Norma K C Ramsay; Leslie L Robison; David Snyder; Anthony Stein; Stephen J Forman; Daniel J Weisdorf
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

3.  Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study.

Authors:  Christopher J Fraser; Smita Bhatia; Kirsten Ness; Andrea Carter; Liton Francisco; Mukta Arora; Pablo Parker; Stephen Forman; Daniel Weisdorf; James G Gurney; K Scott Baker
Journal:  Blood       Date:  2006-06-20       Impact factor: 22.113

4.  A case of chronic kidney disease with thrombotic microangiopathy in a hematopoietic stem cell transplant recipient.

Authors:  Kunihiro Maeda; Keisuke Suzuki; Motonori Mizutani; Hitoshi Watanabe; Norihiro Suga; Wataru Kitagawa; Naoto Miura; Kazuhiro Nishikawa; Kazuharu Uchida; Hirokazu Imai
Journal:  Clin Exp Nephrol       Date:  2010-05-15       Impact factor: 2.801

5.  Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.

Authors:  Areej El-Jawahri; Yi-Bin Chen; Ruta Brazauskas; Naya He; Stephanie J Lee; Jennifer M Knight; Navneet Majhail; David Buchbinder; Raquel M Schears; Baldeep M Wirk; William A Wood; Ibrahim Ahmed; Mahmoud Aljurf; Jeff Szer; Sara M Beattie; Minoo Battiwalla; Christopher Dandoy; Miguel-Angel Diaz; Anita D'Souza; Cesar O Freytes; James Gajewski; Usama Gergis; Shahrukh K Hashmi; Ann Jakubowski; Rammurti T Kamble; Tamila Kindwall-Keller; Hilard M Lazarus; Adriana K Malone; David I Marks; Kenneth Meehan; Bipin N Savani; Richard F Olsson; David Rizzieri; Amir Steinberg; Dawn Speckhart; David Szwajcer; Helene Schoemans; Sachiko Seo; Celalettin Ustun; Yoshiko Atsuta; Jignesh Dalal; Carmem Sales-Bonfim; Nandita Khera; Theresa Hahn; Wael Saber
Journal:  Cancer       Date:  2017-01-19       Impact factor: 6.860

Review 6.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report.

Authors:  Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-19       Impact factor: 5.742

7.  Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Monzr M Al Malki; Nitya Nathwani; Dongyun Yang; Saro Armenian; Sanjeet Dadwal; Jaroslava Salman; Sally Mokhtari; Thai Cao; Karamjeet Sandhu; Michelle Rouse; Matthew Mei; Haris Ali; Pablo Parker; Joseph Alvarnas; Eileen Smith; Margaret O Donnell; Guido Marcucci; David Snyder; Auayporn Nademanee; Stephen J Forman; Anthony Stein; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2018-05-09       Impact factor: 5.742

8.  Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.

Authors:  Areej El-Jawahri; Joseph Pidala; Yoshi Inamoto; Xiaoyu Chai; Nandita Khera; William A Wood; Corey Cutler; Mukta Arora; Paul A Carpenter; Jeanne Palmer; Mary Flowers; Daniel Weisdorf; Steven Pavletic; Samantha Jaglowski; Madan Jagasia; Stephanie J Lee; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-09       Impact factor: 5.742

Review 9.  Allogeneic transplantation for CML in the TKI era: striking the right balance.

Authors:  Andrew J Innes; Dragana Milojkovic; Jane F Apperley
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

Review 10.  Parental stress before, during, and after pediatric stem cell transplantation: a review article.

Authors:  C M J Vrijmoet-Wiersma; R M Egeler; H M Koopman; A Lindahl Norberg; M A Grootenhuis
Journal:  Support Care Cancer       Date:  2009-07-02       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.